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Natural products have been an unprecedented starting point for
drug and agrochemical discovery. They represent the only validated
source of chemical diversity capable of delivering a sustainable pipeline
for novel drug candidates. As of 1990, 80% of clinically used drugs
were natural products or natural product-inspired or semi-synthetic
derivatives. From 1994 to 2007, almost half of the new chemical en-
tities approved by FDA were based on natural products [1]. By the end
of 2013, natural products or their inspired compounds comprised about
40% of the FDA approved drugs [2]. Streptomyces are by far the most
proliﬁc natural product producing organisms and as such this genus has
been the research subjects for lead compound discovery for decades.
Streptomyces natural products display a diverse array of complex che-
mical structures including polyketides, peptides, alkaloids and terpe-
noids. Polyketides (PKSs) produced by Streptomyces contribute many
clinically used drugs including immunosuppressants, antiparasitics and
antitumor agents [3]. Organic chemists have developed many in-
novative regio- and stereo-selective strategies to chemically synthesize
these structurally complex molecules. However, these total synthetic
methods have suﬀered poor atomic economy, which renders them not
economically viable [4]. Microbial fermentation instead is an attractive
method in biopharmaceutical industry to produce these polyketide
drugs. It is common observation that these PKSs are produced by wild-
type Streptomyces strains in a minor amount of materials with the range
of submilligram to milligram per litre of liquid culture in the tamed
conditions. In the past, untargeted random mutagenesis has been ap-
plied with the hope that, after several rounds of mutagenesis, the mu-
tants can generate enhanced titres (preferable grams or kilograms per
litres) for the industry to be economically viable. Although having been
successfully applied to many PKS producing strains to generate clini-
cally used medicines, this method has been considered time-consuming
and extensively laborious, causing diﬃculty in wider applications.
With advance in sequencing and recombinant DNA technology in
the new millennium, we now understand how these chemically com-
plex yet valuable PKSs are produced by Streptomyces. Biosynthetically
the PKS pathways are similar to the fatty acid pathway in which chain
elongation undergoes via a Claisen-like condensation of acyl-coenzyme
A extender units. As with fatty acid synthases, polyketide synthases
(PKSs) can be large multifunctional proteins (Type I) or a set of in-
dividual monofunctional proteins (type II) or a group of multifunctional
enzymes of the chalcone synthase type (type III) [5]. With an ever-
expanding toolbox of biosynthetic components, synthetic biology en-
abling metabolic engineering is an increasingly powerful method to
improve PKS titres and generate novel compounds. This can be ex-
empliﬁed by manipulating regulation and signal transduction to sti-
mulate environmental cues, improving precursor and cofactor pools,
removing or suppressing competing pathways, improving enzyme
conversion rates for bottleneck reactions and overexpressing genes
conferring tolerance for the toxicity of produced metabolites [6].
Among these strategies, enriching the pool of acetyl-CoA, a key pre-
cursor of polyketides, has been widely used for the titre improvement,
by blocking glycolysis or reducing TCA cycle activity to redirect the
carbon ﬂuxes, or transcriptionally enhancing the formation of acetyl-
CoA precursor etc. [3,7].
Due to the importance in lead compound discovery, the biology of
Streptomyces has been well-studies. It is known that natural products are
produced by Streptomyces or other microorganisms via secondary me-
tabolisms. Unlike primary metabolites, which are essential for growth
in all organisms, secondary metabolites are produced in the stationary
phase. During the growth phase in the fermentation, cells utilise ex-
ternal nutrients and grow exponentially. When external nutrients are
expanded, cells stop growing and enter stationary phase, in which
secondary metabolites start to be produced [7]. However, it has re-
mained poorly understood which factor(s) trigger the metabolic switch
from primary metabolisms to secondary metabolisms during the course
of fermentation and how cells divert intracellular precursors from pri-
mary metabolisms to PKS production in stationary phase during fer-
mentation.
Featured in the December issue (vol. 38, pp. 76–83) of Nature
Biotechnology in 2019, a Chinese team led by Professor Lixin Zhang
from East China University of Science and Technology published a
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research article, revealing a breakthrough observation of a process that
channels carbon ﬂux from triacylglycerols (TAGs), accumulated lipids
during the growth phase, into PKS biosynthesis via enzymatic β-oxi-
dation [8]. They applied multi-omics to conﬁrm that the accumulated
TAG pool is the intracellular carbon source for PKS production during
the stationary phase by comparing the metabolomic and transcriptomic
data of wild-type and high-yielding PKS Streptomyces strains. Through
metabolic ﬂux analyses and a series of assays, the team uncovered the
mystery: more degradation of TAGs in the high-yielding strain via
multi-cycle β-oxidation increased cellular acetyl-CoA, as well as redu-
cing equivalents and ATP. The high level of the latter two metabolites
further inhibit TCA cycles, which in turn weakens the carbon ﬂux from
acetyl-CoA to TCA cycle but increases the precursor supply towards
polyketide biosynthesis (Fig. 1). To make good use of this ﬁnding, the
team designed a new strategy named dynamic degradation of TAG
(ddTAG) to rationally control the mobilization of TAGs towards PKS
production during stationary phase of fermentation by overexpressing a
fatty acyl-CoA synthetase (ACS) encoding the gene sco6196 under a
cumate-inducible promoter. The ACS can activate more fatty acids via
thioesteriﬁcation with coenzyme A (CoA) and therefore enhance the β-
oxidation process. This ddTAG module enabled signiﬁcantly improved
titres of four diﬀerent polyketide lead compounds, namely acti-
norhodin, jadomycin B, oxytetracycline and avermectin B1a from four
diﬀerent Streptomyces producing strains in the shake ﬂask fermentation
conditions, respectively, suggesting the wider application of this bio-
technology. Finally, the team applied this ddTAG strategy in the scale-
up industrial bioreactor to persuade the engineered strain A56-DT to
produce 50% higher titres of avermectin B1a to 9.31 g l−1, which is the
highest titre ever reported. Interestingly, a recent report by Alper et al.
demonstrated a similar β-oxidation up-regulation strategy on in-
tracellular lipid pool in the oleaginous yeast Yarrowia liplytica that
enables increased production of a variety of fungal polyketide meta-
bolites, naringenin, resveratrol and bisdemethoxycurcumin in the mu-
tated variants [9]. This observation further demonstrates that rational
control of β-oxidation strategy on lipid mobilization during stationary
phase can be widely applied to enhance microbial polyketide titres for
pharmaceutical production.
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Fig. 1. β-Oxidation up-regulation strategy on in-
tracellular triacylglycerols (TAGs) employed in Ref.
[8]. Intracellular TAGs which accumulate in primary
metabolism are mobilized to produce polyketides
via β-oxidation during stationary phase. Over-
expression of the fatty acyl-CoA synthetase (ACS)
allows overproduction of acyl-CoA to enter β-oxi-
dation cycle, and therefore increasing the cellular
level of acetyl-CoA, the key precursor of polyketides,
as well as reducing equivalents and ATP. The high
level of the latter two metabolites further inhibit
TCA cycles, which in turn weakens the carbon ﬂux
from acetyl-CoA to TCA cycle but increases the
precursor supply towards polyketide biosynthesis.
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